889PPHASE I DOSE-ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF NINTEDANIB (BIBF 1120) IN COMBINATION WITH CARBOPLATIN/PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (ROC)
Del Campo, J.M., Pardo Búrdalo, B., Rodriguez Freixinos, V., Gaba Garcia, L., Gil Martín, M., Oaknin, A., Ballester, A., Sailer, M.O., Merger, M., Morsli, N., Vidal, L.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Phase I Dose-Escalation Study to Determine the Maximum Tolerated Dose (Mtd) of Nintedanib (Bibf 1120) in Combination with Carboplatin/Pegylated Liposomal Doxorubicin (Pld) in Patients (Pts) with Recurrent Ovarian Cancer (Roc)
Del Campo, J.M., Pardo Búrdalo, B., Rodriguez Freixinos, V., Gaba Garcia, L., Gil Martín, M., Oaknin, A., Ballester, A., Sailer, M.O., Merger, M., Morsli, N., Vidal, L.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article